Kyverna Therapeutics, Inc. (KYTX) has issued an announcement.
Kyverna Therapeutics, Inc. presented an update on its leading CAR T-cell therapy candidate, KYV-101, at the EULAR symposium in Vienna on June 14, 2024. The latest data is outlined in their presentation, emphasizing the company’s progress but with a disclaimer that there is no commitment to update the material in the future. The presentation’s details, while not legally filed, can influence future documents if explicitly referenced.
See more insights into KYTX stock on TipRanks’ Stock Analysis page.
